Quality of life and treatment outcomes for relapsed/refractory multiple myeloma with advanced versus conventional immunotherapies.

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This non-interventional observational study will follow about 174 adults with relapsed or refractory multiple myeloma who are starting either advanced immuno-oncology agents (such as bispecific antibodies or antibody-drug conjugates) or conventional immunotherapies. Participants first undergo screening and enrollment with collection of individualized treatment value priorities, then enter a treatment phase where they receive physician-directed therapy and complete patient-reported outcome measures on Day 1 of each treatment cycle alongside routine efficacy and safety assessments. The study captures real-world effectiveness, adverse events, and quality-of-life measures without altering clinical care, and ends with a final end-of-study visit to summarize outcomes. Eligibility requires prior exposure to a proteasome inhibitor, an immunomodulatory drug, and a monoclonal antibody.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Male or female aged 19 years or older.
* Diagnosed with multiple myeloma and have been previously treated with at least one proteasome inhibitor, one immunomodulatory drug, and one monoclonal antibody treatment (i.e., exposed to all three classes of immunotherapy agents).
* Diagnosed with relapsed or refractory multiple myeloma between the IRB approval date and December 2025, and scheduled to start treatment with either advanced immuno-oncology agents or conventional immuno-oncology agents within one month from screening.
* Provided written informed consent after receiving detailed explanation about the study and voluntarily agreed to participate and comply with study requirements.

Exclusion Criteria:

* Those who do not agree to participate in the study.
* Patients diagnosed with plasma cell disorders other than multiple myeloma (e.g., lymphoma, POEMS syndrome).
* Individuals unable to read and understand documents written in Korean.

Where it's running

• Seoul St. Mary Hospital
  Seocho, Seoul, South Korea Recruiting

Study contacts

• Study coordinator: Sung-Soo Park, MD.PhD
• Email: sspark@catholic.ac.kr
• Phone: +82-10-3782-2736

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Cognitive changes after BCMA CAR-T in multiple myeloma

  This study tests whether cognitive function changes over time in adults with relapsed or refractory multiple myeloma who receive BCMA CAR-T therapy.

  Recruiting Wake Forest University Health Sciences · Charlotte, North Carolina · NCT07740317

• GPRC5D-targeted PET/CT imaging in plasma cell disorders

  This study tests a new GPRC5D-targeted PET/CT imaging method in adults with plasma cell disorders to see if it detects disease better or differently than standard imaging.

  Recruiting Phase 1 Peking University First Hospital · Beijing, Beijing Municipality · NCT07660939

• Gustabor: Tailored AI Nutrition for Taste Changes During Cancer Therapy

  This trial tests whether personalized, AI-assisted dietary advice helps people with taste changes from cancer treatment compare to general dietary guidance.

  Recruiting at 2 sites Wuerzburg University Hospital · Augsburg, Bavaria and 5 other locations · NCT07649681

• Personalising Myeloma Treatment Based on Initial Response and Fitness

  This trial tests whether adjusting treatment after six months of the standard DRd therapy, based on a patient’s response and fitness, can improve outcomes for older, transplant-ineligible patients with myeloma.

  Recruiting Phase 3 University of Leeds · Bristol and 4 other locations · NCT07649525

• Elranatamab given as outpatient in relapsed or refractory multiple myeloma

  This study tests a bispecific antibody called elranatamab, given in an outpatient setting to adults with relapsed or refractory multiple myeloma who have had prior therapies.

  Recruiting at 6 sites Phase 2 SCRI Development Innovations, LLC · Denver, Colorado and 5 other locations · NCT07637578

• CM336 with Isatuximab for Newly Diagnosed Myeloma with Kidney Impairment

  This study tests a CM336 and isatuximab regimen in adults with newly diagnosed multiple myeloma and kidney trouble to see if it helps.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin · NCT07585760

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.